Loading
A phase 2 trial of Capecitabine in triple-negative breast cancer, run by Processa Pharmaceuticals, now recruiting.
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT06568692 by Processa Pharmaceuticals, with 90 participants planned, started 2024-10-02 and due to reach its primary completion in 2026-09. Interventions recorded: PCS6422 and capecitabine and Capecitabine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Capecitabine, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Cytotoxic chemotherapy and the tag pipeline.